Peter L Anderson

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission
    Peter L Anderson
    The Department of Pharmaceutical Sciences, University of Colorado Denver, 12850 E Montview Blvd, Aurora, CO 80045, USA
    J Antimicrob Chemother 69:2470-6. 2014
  2. pmc Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
    Peter L Anderson
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA
    J Antimicrob Chemother 64:1071-9. 2009
  3. pmc Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
    Peter L Anderson
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USA
    J Antimicrob Chemother 66:240-50. 2011
  4. pmc Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine
    Joseph E Rower
    University of Colorado Denver, Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Aurora, Colorado, USA
    Antimicrob Agents Chemother 56:3011-9. 2012
  5. pmc Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure
    Jose R Castillo-Mancilla
    Division of Infectious Diseases, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA
    AIDS Res Hum Retroviruses 29:384-90. 2013
  6. ncbi request reprint A population pharmacokinetic-pharmacogenetic analysis of atazanavir
    Deidre A Kile
    Colorado Health Outcomes Program, University of Colorado Denver School of Medicine, Aurora, USA
    AIDS Res Hum Retroviruses 28:1227-34. 2012
  7. pmc Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection
    Lane R Bushman
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Mail Stop V20 C238, 12850 E Montview Blvd, Aurora, Colorado 80045, USA
    J Pharm Biomed Anal 56:390-401. 2011
  8. pmc Clinical pharmacokinetics of antiretroviral drugs in older persons
    John C Schoen
    University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, Aurora, CO, USA
    Expert Opin Drug Metab Toxicol 9:573-88. 2013
  9. doi request reprint Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin
    Christina L Aquilante
    PharmD, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, 12850 East Montview Blvd, Mail Stop C238, Room V20 4103, Aurora, CO 80045, USA
    J Clin Pharmacol 52:1725-38. 2012
  10. pmc Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men
    Peter L Anderson
    University of Colorado Denver, Aurora, CO 80045, USA
    Sci Transl Med 4:151ra125. 2012

Research Grants

Collaborators

Detail Information

Publications19

  1. pmc Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission
    Peter L Anderson
    The Department of Pharmaceutical Sciences, University of Colorado Denver, 12850 E Montview Blvd, Aurora, CO 80045, USA
    J Antimicrob Chemother 69:2470-6. 2014
    ..This study evaluated the relationship between intracellular tenofovir diphosphate concentrations in peripheral blood mononuclear cells and prophylactic efficacy in a macaque model for HIV pre-exposure prophylaxis (PrEP)...
  2. pmc Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
    Peter L Anderson
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA
    J Antimicrob Chemother 64:1071-9. 2009
    ..The objective of this study was to compare atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors...
  3. pmc Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
    Peter L Anderson
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USA
    J Antimicrob Chemother 66:240-50. 2011
    ..The current state of knowledge in these areas is summarized and the future utility of intracellular pharmacokinetics/pharmacodynamics for the PrEP field is discussed...
  4. pmc Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine
    Joseph E Rower
    University of Colorado Denver, Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Aurora, Colorado, USA
    Antimicrob Agents Chemother 56:3011-9. 2012
    ..This information extends knowledge of ZDV and 3TC cellular pharmacology in vivo and provides new leads for future cellular pharmacology studies aimed at optimizing HIV prevention/treatment with these agents...
  5. pmc Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure
    Jose R Castillo-Mancilla
    Division of Infectious Diseases, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA
    AIDS Res Hum Retroviruses 29:384-90. 2013
    ..4x; r(2)=0.96 and y=0.8x; r(2)=0.99, respectively. We conclude that DBSs offer a convenient measure of recent (TFV/FTC) and cumulative (TFV-DP in RBCs) drug exposure with potential application to adherence monitoring...
  6. ncbi request reprint A population pharmacokinetic-pharmacogenetic analysis of atazanavir
    Deidre A Kile
    Colorado Health Outcomes Program, University of Colorado Denver School of Medicine, Aurora, USA
    AIDS Res Hum Retroviruses 28:1227-34. 2012
    ....
  7. pmc Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection
    Lane R Bushman
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Mail Stop V20 C238, 12850 E Montview Blvd, Aurora, Colorado 80045, USA
    J Pharm Biomed Anal 56:390-401. 2011
    ..This document outlines method development, validation, and application to clinical research...
  8. pmc Clinical pharmacokinetics of antiretroviral drugs in older persons
    John C Schoen
    University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, Aurora, CO, USA
    Expert Opin Drug Metab Toxicol 9:573-88. 2013
    ..Most studies did not detect substantial associations between drug exposures and age...
  9. doi request reprint Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin
    Christina L Aquilante
    PharmD, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, 12850 East Montview Blvd, Mail Stop C238, Room V20 4103, Aurora, CO 80045, USA
    J Clin Pharmacol 52:1725-38. 2012
    ....
  10. pmc Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men
    Peter L Anderson
    University of Colorado Denver, Aurora, CO 80045, USA
    Sci Transl Med 4:151ra125. 2012
    ..Prophylactic benefits were observed over a range of doses and drug concentrations, suggesting ways to optimize PrEP regimens for this population...
  11. pmc Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry
    Leah C Jimmerson
    Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado Denver, Anschutz Medical Campus, 12850 East Montview Blvd, C 238 V20, Aurora, CO 80045, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 944:18-24. 2014
    ..Correlation of RBV in DBS versus in plasma yielded r(2)≥0.98 demonstrating that DBS can be used as an alternative to plasma for PK-PD studies in human subjects. ..
  12. pmc Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma
    Joseph E Rower
    School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA
    Biomed Chromatogr 26:12-20. 2012
    ..The value of the high sensitivity was demonstrated by quantitation of approximately 100 existing samples that had ZDV below the limit of quantitation using a previously validated, less sensitive HPLC-UV method utilized in the laboratory...
  13. pmc Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment
    Michael F Wempe
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado 80045, USA
    Drug Metab Dispos 39:522-7. 2011
    ..Therefore, other pharmacological factors are likely to explain the apparent lack of effect of genetically determined CYP3A5 expressor status on atazanavir oral clearance in African Americans from the previous study...
  14. pmc Review and management of drug interactions with boceprevir and telaprevir
    Jennifer J Kiser
    Schools of Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA
    Hepatology 55:1620-8. 2012
    ..This review highlights the pharmacologic characteristics and drug-interaction potential of BOC and TPV and provides guidance on the management of drug interactions with these agents...
  15. ncbi request reprint Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients
    Jennifer J Kiser
    School of Pharmacy, University of Colorado at Denver, Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:298-303. 2008
    ..Nucleos(t)ide reverse transcriptase inhibitors (NRTIs), such as tenofovir, require intracellular phosphorylation for pharmacologic activity. Drug transporters may contribute to the intracellular disposition of NRTIs...
  16. pmc Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers
    Jennifer J Kiser
    Department of Pharmaceutical Sciences, University of Colorado Denver, 12700 E 19th Avenue, P15 C238, Research Complex 2, Aurora, CO 80045, USA
    Antimicrob Agents Chemother 54:4999-5003. 2010
    ....
  17. pmc Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection
    K Rivet Amico
    Center for Health Intervention and Prevention, University of Connecticut, Storrs, CT Applied Health Research, Brighton, MI Gladstone Institutes, San Francisco, CA University of California, San Francisco, CA Center for AIDS Prevention Studies, University of California, San Francisco, CA Investigaciones Medicas en Salud, Lima, Peru and University of Colorado Denver, Aurora, CO
    J Acquir Immune Defic Syndr 66:530-7. 2014
    ....
  18. pmc Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro
    Peter L Anderson
    Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO 80262, USA
    J Antimicrob Chemother 62:738-45. 2008
    ....
  19. doi request reprint Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions
    Laura Enomoto
    University of Colorado Denver, Aurora, USA
    AIDS Res Hum Retroviruses 27:47-55. 2011
    ..In conclusion, AZT had the most pronounced inhibitory effect on CMI. Further studies are warranted to determine the clinical significance of this observation...

Research Grants5

  1. Sex and disease dependent nucleoside analog toxicity
    Peter Anderson; Fiscal Year: 2009
    ..The knowledge to be gained addresses our long-term objective to discover the determinants of drug responses and to utilize the information to improve drug safety. ..
  2. Sex and disease dependent nucleoside analog toxicity
    Peter Anderson; Fiscal Year: 2005
    ..The knowledge to be gained addresses our long-term objective to discover the determinants of drug responses and to utilize the information to improve drug safety. ..
  3. Sex and disease dependent nucleoside analog toxicity
    Peter Anderson; Fiscal Year: 2006
    ..The knowledge to be gained addresses our long-term objective to discover the determinants of drug responses and to utilize the information to improve drug safety. ..
  4. Sex and disease dependent nucleoside analog toxicity
    Peter Anderson; Fiscal Year: 2007
    ..The knowledge to be gained addresses our long-term objective to discover the determinants of drug responses and to utilize the information to improve drug safety. ..